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Abstract
Background: Germline mutations in the folliculin (FLCN) gene are associated with the development of Birt-Hogg-
Dubé syndrome (BHDS), a disease characterized by papular skin lesions, a high occurrence of spontaneous
pneumothorax, and the development of renal neoplasias. The majority of renal tumors that arise in BHDS-affected
individuals are histologically similar to sporadic chromophobe renal cell carcinoma (RCC) and sporadic renal
oncocytoma. However, most sporadic tumors lack FLCN mutations and the extent to which the BHDS-derived renal
tumors share genetic defects associated with the sporadic tumors has not been well studied.
Methods: BHDS individuals were identified symptomatically and FLCN mutations were confirmed by DNA
sequencing. Comparative gene expression profiling analyses were carried out on renal tumors isolated from
individuals afflicted with BHDS and a panel of sporadic renal tumors of different subtypes using discriminate and
clustering approaches. qRT-PCR was used to confirm selected results of the gene expression analyses. We further
analyzed differentially expressed genes using gene set enrichment analysis and pathway analysis approaches.
Pathway analysis results were confirmed by generation of independent pathway signatures and application to
additional datasets.
Results: Renal tumors isolated from individuals with BHDS showed distinct gene expression and cytogenetic
characteristics from sporadic renal oncocytoma and chromophobe RCC. The most prominent molecular feature of
BHDS-derived kidney tumors was high expression of mitochondria-and oxidative phosphorylation (OXPHOS)-
associated genes. This mitochondria expression phenotype was associated with deregulation of the PGC-1a-TFAM
signaling axis. Loss of FLCN expression across various tumor types is also associated with increased nuclear
mitochondrial gene expression.
Conclusions: Our results support a genetic distinction between BHDS-associated tumors and other renal
neoplasias. In addition, deregulation of the PGC-1a-TFAM signaling axis is most pronounced in renal tumors that
harbor FLCN mutations and in tumors from other organs that have relatively low expression of FLCN. These results
are consistent with the recently discovered interaction between FLCN and AMPK and support a model in which
FLCN is a regulator of mitochondrial function.
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Renal cell carcinomas (RCC) represent the most com-
mon type of tumors that arise within the adult kidney.
They can be divided into several subtypes - clear cell,
papillary, chromophobe, and collecting duct - based on
differences in cellular morphology, gene expression, and
cytogenetic and genetic abnormalities that are found
within the tumor cells [1-4]. The two most common
types of RCC are clear cell and papillary, which together
account for approximately 85-90% of RCCs. Chromo-
phobe RCC accounts for an additional 5% of renal
tumors, and a histologically similar subtype, renal onco-
cytoma, represents another 5% (see [5,6] for recent
reviews). Although the neoplastic cells of chromophobe
RCC and renal oncocytoma share morphological fea-
tures, renal oncocytomas are generally asymptomatic
and nearly always present as localized lesions with low
metastatic potential [7].
Though most renal tumors occur sporadically (~95%),
several hereditary syndromes are associated with a high
risk of renal tumor development. These syndromes
include von Hippel-Lindau disease, hereditary papillary
RCC, hereditary leiomyomatosis and renal cancer, and
Birt-Hogg-Dubé syndrome (BHDS) [8]. In von Hippel-
Lindau disease, a rare germline mutation in the VHL
gene is associated with development of the disease
(reviewed in [9]). Individuals with von Hippel-Lindau
disease are predisposed to the development of renal
tumors of the clear cell histology. In addition, somatic
mutations in the VHL gene are also found in the major-
ity of the sporadic cases of clear cell RCC [10]. Birt-
Hogg-Dubé syndrome is an extremely rare syndrome-
approximately 200 families have been described as
having BHDS worldwide [11,12]. Germline inheritance
of a mutated allele of the folliculin (FLCN) gene, located
at chromosome location 17p11.2, is strongly associated
with individuals that develop BHDS [13]. In individuals
afflicted with BHDS, the majority (~85%) of renal
tumors that develop are histologically similar to chro-
mophobe RCC or described as oncocytic hybrid tumors,
with portions appearing as both renal oncocytoma and
chromophobe RCC [14,15]. Unlike VHL,s o m a t i cm u t a -
tions in the FLCN gene are not strongly associated with
the development of sporadic renal oncocytoma and
chromophobe RCC [16,17]. As such, the role that FLCN
plays in the development of sporadic renal oncocytoma,
chromophobe RCC, and other sporadic tumors remains
unclear.
The folliculin gene encodes a highly conserved, 64kD
protein with no known functional domains. Recent
reports support its role as a tumor suppressor [18,19]
and in energy-related signaling, involving the mTOR
and AMPK pathways [20-22]. FLCN has been shown to
interact with AMPK through the binding of two inter-
mediary proteins, folliculin interacting protein 1 and fol-
liculin interacting protein 2 (FNIP1/2) and the activity
of FLCN may be altered by its subsequent phosphoryla-
tion by AMPK or localization to the cytoplasm with its
binding partners, or a combination of these two
mechanism [20,23,24]. As indicated previously, while
germline mutations in FLCN c a u s eB H D S ,t h e s em u t a -
tions are not strongly associated with either sporadic
chromophobe RCC or renal oncocytoma [17]. The most
well characterized somatic mutations found in these two
sporadic tumor subtypes are mutations within the mito-
chondrial genome [25-29]. Renal oncocytoma, in parti-
cular, is characterized by the accumulation of somatic
mutations in mtDNA that inactivate subunits of mito-
chondrial complex I and other members of the electron
transport chain, severely limiting ATP production
[26,27]. In addition, both sporadic renal oncocytoma
and chromophobe RCC possess mitochondria-dense
cytoplasm and aberrant expression of genes associated
with oxidative phosphorylation (OXPHOS) [25,27,30].
However, the mechanism by which these mitochondrial
defects contribute to tumor development remains
unclear and the gene expression and cellular phenotypes
observed are thought to represent feedback mechanisms
to compensate for mitochondrial impairment.
While expression of some key markers of renal tumors
have been examined in a single BHDS-derived tumor
[31], we conducted gene expression profiling of multiple
renal tumors that arose in individuals with BHDS along
with sporadic renal oncocytoma and chromophobe RCC
to develop a better understanding of the underlying
molecular genetics of these tumors. We found that
tumors that arose in individuals with BHDS were geneti-
cally distinct from sporadic tumors, showing distinct
gene expression and cytogenetic characteristics. How-
ever, similar to sporadic renal oncocytoma and chromo-
phobe RCC, BHDS-derived renal tumors displayed high
expression of mitochondria and OXPHOS-associated
genes. Indeed, the expression of mitochondria and
OXPHOS-associated genes was even more pronounced
in the BHDS-derived tumors than the other sporadic
tumors and was correlated to increased expression of
key mitochondria transcriptional regulators. We have
also noted an inverse correlation between FLCN expres-
sion and mitochondria- and OXPHOS-associated genes
across a variety of tumor types, most evident in tumors
that possessed relatively low levels of FLCN and enrich-
ment in mitochondria- and OXPHOS-associated gene
expression. Taken together, our data suggest that FLCN
has an important role in the regulation of genes asso-
ciated with mitochondria and OXPHOS in BHDS-
derived tumors and possibly others.
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Tissue sample collection and DNA sequencing
Internal review board approval was obtained from each
participating institution for the renal neoplasms under
study. Samples isolated from individuals afflicted with
BHDS were flash-frozen in liquid nitrogen and stored at
-80°C following excision from patients as previously
described [32]. FLCN mutation status was confirmed
through DNA extraction from tumor samples and
sequencing, as described previously [33], using primer
sequences from Nickerson et al.[ 1 3 ] .T h eh i s t o l o g i c a l
classification and FLCN mutation information for the
BHDS-derived renal tumor samples are given in Addi-
tional file 1 Table S1.
Gene expression profiling datasets
RNA was isolated and expression profiles generated from
BHDS-derived tumor samples using the Affymetrix HG-
U133 Plus 2.0™chipset as previously described [32]. These
data are available at the Gene Expression Omnibus
(GEO, GSE21816). Expression profiles for the remaining
RCC subtypes and non-RCC tumors used in the analysis
are publicly available from the GEO database (GSE8271,
GSE11024, GSE11016, GSE7023, and GSE2109). All data
analysis was performed using software available from the
BioConductor Project (version 2.5) and the R statistical
environment v. 2.10.1 [34,35]. Prior to analysis, the
robust multi-chip average (RMA), as implemented in the
Affy package (1.24.2), was used for background correc-
tion and normalization of raw expression image intensi-
ties using updated probeset mapping [36] and data were
normalized to corresponding normal tissue type. The
technical replicate expression datasets from the DT017
sample of patient BHD1 were averaged prior to discrimi-
nate gene and gene set analyses.
Validation of gene expression microarray data by
qRT-PCR
Single-step, quantitative reverse transcription-PCR
(qRT-PCR) was performed to validate expression levels
for the following genes: PVALB, CDH19, RGS20,a n d
LRRTM4,w i t ht h eGAPDH gene as a control. To per-
form the single-step qRT-PCR, we used the Power
SYBR® Green PCR Master Mix with Taqman® Gold RT-
PCR enzymes (Applied Biosystems, Foster City, CA).
We also conducted qRT-PCR using Taqman® assays
(Applied Biosystems) using the manufacturer’sp r o t o c o l
for the following genes: F L C N ,F N I P 2 ,P P A R G C 1 A ,
PVALB, RGS20, TFAM, and TSC1. The reactions were
run on an ABI 7500 Fast Real-Time PCR system using a
dissociation curve analysis for the SYBR Green assays to
confirm primer specificity. We used the PerlPrimer soft-
ware [37] to design PCR primers within the exons that
were interrogated by the Affymetrix expression chips.
Primer sequences and assay ids have been made avail-
able in Additional file 1 Table S4.
Clustering and differential gene expression
Prior to clustering of all RCC samples, the 1000 most
variable genes were isolated using an interquartile range
filter of greater than 1.54. Clustering was performed
using Euclidean distance with complete linkage. For the
clustering of sporadic chromophobe RCC, sporadic onco-
cytoma, and BHDS-derived renal tumor samples, the
1500 most variable genes were isolated, corresponding to
an interquartile range filter of greater than 0.79. Eucli-
dean distance with average linkage was used, followed by
resampling for node support. Bootstrap resampling for
10,000 replications and a relative sample size of 1 was
used to generate the bootstrap probability values, as
implemented in the pvclust package v.1.2-1 [38].
Discriminatory genes were identified using a moder-
ated t-statistic as implemented in the limma package.
Significance values were adjusted to correct for multiple
testing using the Benjamini and Hochberg method [39].
Genes with false discovery rate (FDR) values less than
0.01 were reported as significant. Given that the sample
size of BHDS-derived tumors was disproportionate to
the number of either sporadic oncocytoma or chromo-
phobe RCC tumors, we conducted a permutation test to
decide whether the distinctiveness of BHDS-derived
tumors was a result of bias from a sample size effect.
The test was conducted using 1000 iterations comparing
the entire data set from the six BHDS-derived tumors to
five randomly selected oncocytoma data sets (without
replacement). The number of significantly differentially
expressed genes from this BHD-oncocytoma comparison
was greater than the number derived from a similar dis-
criminate analysis of five randomly selected oncocytoma
data sets with the remaining six oncocytoma data sets in
all of 1000 permutations. Likewise, a similar permuta-
tion test using the six BHD and six randomly selected
chromophobe RCC datasets was found to contain a
greater number of differentially expressed genes than a
comparison of six randomly chosen chromophobe with
the remaining six chromophobe datasets in all of 1000
permutations.
Gene set enrichment analyses
Parametric gene set enrichment was used to identify
chromosomal expression abnormalities using gene sets
corresponding to chromosomal arms as implemented in
the reb package [40]. For pathway analysis 1892 gene
sets were obtained from the Molecular Signatures Data-
base v2.5 (MsigDB, http://www.broadinstitute.org/gsea/
msigdb/). These gene sets were curated from multiple
sources including online pathway databases, biomedical
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metric gene set enrichment analysis method as imple-
mented in the PGSEA package was used generate
enrichment scores for each pathway within each tumor
sample using corresponding non-diseased kidney tissue
as a reference. A moderated t-statistic as implemented
in the limma package [41] was used to identify gene set
enrichment scores that could discriminate between sub-
types. In order to visualize the fraction of genes that
overlapped between deregulated gene sets, we calculated
pair-wise dissimilarity (D) scores using the formula:
D
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,w h e r eNA∩B is the num-
ber of genes in common between gene sets A and B and
NA and NB are the numbers of genes making up gene
sets A and B. The dissimilarity score was used to com-
pute a hierarchical clustering dendrogram using Eucli-
dean distance with average linkage.
PGC-1a signature generation
We produced a gene overexpression signature of PGC-
1a using gene expression data obtained from the com-
parison of PGC-1a transfected HepG2 cells to mock
transfected cells (GSE5968). A moderated t-statistic was
used to identify genes with expression differences that
were both significant (FDR
Results
BHDS tumors have distinct gene expression patterns
Although BHDS is exceedingly rare, it is important to
determine whether molecular analysis of BHDS-derived
renal tumors could give insight into the development of
sporadic chromophobe RCC and renal oncocytoma as
well as the cellular role of FLCN-related signal transduc-
tion. Therefore, we performed gene expression profiling
on a set of renal tumors isolated from individuals
afflicted with BHDS. We confirmed the presence of
FLCN mutations in these tumors (Additional file 1
Table S1). To determine how the BHDS-derived renal
tumors were related to other subtypes of renal cell car-
cinomas, we used unsupervised hierarchical clustering
with the most variable set of expressed genes (Figure
1A). Sporadic renal oncocytoma and chromophobe RCC
have an overall distinct pattern of gene expression rela-
tive to other RCC subtypes and consistent with the pre-
viously described histological similarity, the expression
characteristics of BHDS-derived tumors were more simi-
lar to sporadic chromophobe and renal oncocytoma
than the other RCC subtypes (Figure 1A). Sporadic
renal oncocytoma and chromophobe RCC are thought
to arise from cells that make up the distal convoluted
tubule (DCT) portion of nephrons within the kidney [1].
To examine the tissue of origin of the BHDS-derived
tumors, we assessed the expression of the distal convo-
luted tubule marker, PVALB [42]. This gene is expressed
in sporadic renal oncocytoma and chromophobe RCC,
b u ti sa b s e n to rs i g n i f i c a n t ly lower in gene expression
array data of clear cell and papillary tumors thought to
derive from the proximal convoluted tubule and the
urothelial/transitional cell carcinomas that arise from
cells of the urinary tract (Figure 1C). Although not
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Figure 1 BHD tumors represent a distinct class of renal cell
carcinoma. A) Hierarchical clustering of renal tumor samples (BHDS,
N = 6; ON, N = 11; CH, N = 12; CC, N = 10; PAP, N = 22; UR, N =
10) and non-diseased renal tissue (N = 12) using the expression
data from the 1000 most variable genes. B) Unsupervised clustering
of BHD, ON, and CH tumor samples using gene expression data
from the 1500 most variable genes within this group. Bootstrap
probability values are given for the major nodes. C) Expression of
the distal convoluted tubule marker parvalbumin, PVALB, in the RCC
tumor sample data used in A. D) qRT-PCR validation of expression
of PVALB, along with two identified genes with high BHDS tumor-
specific expression, cadherin 19 (CDH19) and regulator of G-protein
signaling 20 (RGS20). BHD, N = 2; CC, N = 3; NO, N = 3; ON, N = 3.
E) Gene expression heatmap displaying expression values after
median centering for the fifty genes most up-regulated in BHDS-
derived tumors compared to sporadic chromophobe RCC and renal
oncocytoma from A. Abbreviations: NO, normal; ON, renal
oncocytoma; CH, chromophobe RCC; CC, clear cell RCC; PAP,
papillary RCC; UR, urothelial/TCC RCC.
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derived tumors, supporting the notion that these tumors
also arise from the distal convoluted tubule[31]. We
further examined FLCN expression in BHDS-derived
tumors as well as renal oncocytoma and chromophobe
RCC. We did not find a significant difference in the
FLCN transcript levels in the s et u m o r sb yt h eg e n e
expression array data nor by qRT-PCR of a subset of
samples (Additional file 2, Figure S1A and data not
shown).
In the initial gene expression analysis the BHDS-
derived tumors formed a distinct branch in the cluster-
ing diagram (Figures 1A, B). These gene expression
differences were not due to a sample batch effect since
these renal tumors were collected at multiple institu-
tions and the gene expression profiles were generated at
various times between 2004 through 2009 using multiple
chip lots (Additional file 1, Table S1 and data not
shown). A more focused examination of the DCT-
derived tumors confirmed those from patients with
BHDS possess distinct expression characteristics with
strong node support as inferred by gene resampling
(Figure 1B). Several genes were differentially expressed
between BHDS-derived tumors and renal oncocytoma
(n = 401) and BHDS-derived tumors and chromophobe
RCC (n = 2922; FDR 1, Table S2). For comparison, we
found 1050 differentially expressed genes between
sporadic oncocytoma and chromophobe RCC. More-
over, we saw few, if any, gene differences when we per-
formed resampling with the discriminate analysis within
either the sporadic renal oncocytoma or sporadic chro-
mophobe samples, indicating the high numbers of dif-
ferentially expressed genes between tumor subtypes
were not due to differences in sample size between the
tumor subtypes (p < 0.001, see Methods). The molecular
distinction between BHDS-derived tumors, sporadic
renal oncocytoma, and sporadic chromophobe RCC is
in contrast to the similarities of VHL disease-associated
tumors with sporadic clear cell RCC. In those studies,
no significant differences in gene expression were identi-
fied between the two entities [43]. Together, the gene
expression analyses indicate that distinctions exist
between BHDS-derived renal tumors and other RCC
subtypes similar in magnitude to those between the
other recognized subtypes of RCC, such as oncocytoma
and chromophobe RCC. Notable genes that are more
highly expressed in BHDS-derived tumors when com-
pared to sporadic renal oncocytoma and chromophobe
RCC include CDH19, RSG20, DAPL1, LRRTM4,a n d
HHATL (Figure 1EAdditional file 2, Figure S2, and
Additional file 1, Table S2). We validated the expression
levels of PVALB and three of the most significantly
over-expressed genes, CDH19 (cadherin 19, type 2),
RGS20 (regulator of G-protein signaling 20), and
LRRTM4 (leucine rich repeat transmembrane neuronal
4) using qRT-PCR (Figure 1DAdditional file 2, Figures
S1B-C, and data not shown). We chose to validate these
particular genes for their consistently high expression in
BHD-derived tumor samples, their low expression in the
other RCC subtypes examined.
BHDS-derived tumors lack evidence of cytogenetic
features present in sporadic oncocytoma and
chromophobe RCC tumors
Several studies have shown that is possible to detect
both chromosomal translocations[44] and gains and
losses of large chromosomal regions through examina-
tion of gene expression data [45]. To identify potential
chromosomal abnormalities that exist in BHDS samples,
we examined the gene expression data for chromosome-
based changes in gene expression that reflect cytoge-
netic changes such as chromosomal amplifications or
deletions [41,45]. As with previous cytogenetic studies,
our analysis predicted losses of chromosomes 1, 2, 6, 10,
and 17 in chromophobe RCC and, with the exception of
chromosome 1, a lack of large chromosomal abnormal-
ities in renal oncocytoma samples (Figure 2A) [46]. In
addition, evidence of a recently described abnormality of
chromosome 19 (chromosomal gains and somatically
paired chromosomes) was also apparent in both chro-
mophobe RCC and renal oncocytoma data [47]. Though
we predicted one BHDS-derived tumor sample (BHD4,
Additional file 1, Table S1) contains multiple abnormal-
i t i e si n v o l v i n gc h r o m o s o m e s2 ,3 ,4 ,5 ,6 ,1 3 ,a n d1 8 ,a
phenomenon that is sometimes observed in sporadic
cases of renal oncocytoma [48], the tumor possessed
histology typical of hybrid oncocytic-chromophobe
BHDS-derived tumors (Additional file 2, Figures S3A-B).
The BHDS-derived tumors appeared mostly devoid of
chromosomal abnormalities that are typical of the
sporadic tumors. Although the BHDS-derived tumors
did not show loss of chromosome 17p as described in a
cell line recently established from a renal cell carcinoma
of a patient with BHDS [49], the resolution of this
approach does not allow us to exclude the presence of
small focal deletions. In addition, sporadic renal oncocy-
tomas can be partitioned into two mutually exclusive
groups based on cytogenetic features. One group of
tumors possesses a loss of chromosome 1 and the other
group of tumors has a translocation of chromosome
11q13 that has a breakpoint proximal to the cyclin D1
(CCND1) gene [50]. Consistent with this finding, we
identified a subgroup of renal oncocytomas with high
CCND1 expression (N = 6, Figures 2B, C) that were
independent of renal oncocytomas with a predicted loss
of chromosome 1 (Figure 2A). None of the BHDS-
derived tumors show evidence of the CCND1 associated
translocation of 11q13 or loss of chromosome 1. Taken
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files and differences in predicted chromosomal abnorm-
alities suggest that BHDS-derived renal tumors
represent a genetically distinct type of renal tumor.
A mitochondrial gene expression phenotype is a
prominent feature of BHDS-derived tumors
The deregulation of signal transduction pathways have
been identified through examining gene expression data
of renal tumors in several cases, including the deregula-
tion of VHL, MYC, PI3K, E2F, and OXPHOS in clear
cell, papillary, transitional cell carcinoma of the renal
pelvis, Wilms’ tumor, and renal oncocytoma, respec-
tively [51-54]. For example, inactivation of the VHL
gene by somatic mutation is a common feature of clear
cell subtype of RCC. Cells that lack a functional VHL
protein are unable to degrade the hypoxia inducible
transcription factor (HIF). As a consequence these cells
have uncontrolled expression of genes controlled by the
HIF transcription factor. When parametric gene set
enrichment analysis (PGSEA) is used in conjunction
with gene sets (n = 1892) obtained from the Molecular
Signatures Database (MSigDB, see Methods), four of the
top five most significantly deregulated pathways unique
to the clear cell RCC subtype were associated with a cel-
lular hypoxia phenotype (Figure 3A, B). In a similar
comparison of BHDS-derived tumors with the other
RCC subtypes, the top five most significantly deregu-
lated pathways were associated with OXPHOS or mito-
chondria (Figure 3A, C). This result is consistent with
the high mitochondria and OXPHOS-associated gene
expression observed in both sporadic oncocytoma and
chromophobe RCC, tumors known to contain an abun-
dance of mitochondria. In this regard, BHDS-derived
tumors are similar to the other sporadic DCT-derived
tumors. Since our analyses of individual gene expression
supported distinctions between BHDS-derived tumors
and sporadic renal oncocytoma and chromophobe RCC,
we used PGSEA to assess whether any gene sets were
uniquely enriched in BHDS-tumors. For clarity in pre-
sentation, we have organized these differentially
expressed gene sets by hierarchical clustering based on
the percentage of overlapping genes within gene sets
(see Materials and Methods). In this way, gene sets that
were highly redundant (i.e. contained a large percentage
of overlapping genes) were located within the same
branch of the clustering dendrogram. Somewhat surpris-
ingly, several gene sets that were associated with mito-
chondrial function were also identified as being
significantly up-regulated in BHDS-derived tumors
when compared to sporadic renal oncocytoma and chro-
mophobe RCC (Figure 3D, E). These enriched gene sets
of the BHDS-derived tumors included two hand-curated
gene sets reflective of peroxisome proliferator-activated
receptor g coactivator 1a (PGC-1a,e n c o d e db yt h e
PPARGC1A gene) activation, MOOTHA_VOXPHOS
and PGC[55]. A full list of the pathways most deregu-
lated in BHDS-derived tumors is included as Additional
file 1, Table S3.
An expression phenotype involving the PGC-1a-TFAM
signaling axis is unique to BHDS-derived tumors
T h ep r e s e n c eo fFLCN mutations in BHDS-derived
tumors suggested we might be able to identify signal
transduction events associated with FLCN function
(Figure 4A). Previous studies of the FLCN gene product
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Figure 2 BHD tumors do not share the cytogenetic features of
sporadic chromophobe RCC and renal oncocytoma. A) CGMA
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AMP-activated protein kinase (AMPK) and activation of
the mTOR signalling pathway. Specifically, FLCN forms
a complex with folliculin interacting protein 1 or 2
(FNIP1 or FNIP2) and the FLCN-FNIP complex binds
to AMPK [20,23,24]. When we examined twelve genes
encoding the proteins described in Figure 4A (AKT1,
FLCN, FNIP1, FNIP2, PIK3C3, PPARGC1A, PRKAA2,
RICTOR, RPTOR, TFAM, TSC1,a n dTSC2)i no u rg e n e
expression array data, we noticed a slightly elevated
level of FNIP1 expression in BHDS-derived tumors (data
n o ts h o w n )a n dt h a tFNIP2 was highly deregulated in
BHDS-derived tumors, suggesting that these proteins
are relevant to FLCN signaling in renal tumor cells (Fig-
ure 4BAdditional file 2, Figure S1D). While FNIP1 and
FNIP2 share a C-terminal protein domain that binds
FLCN, their respective N-terminal domains are quite
d i s s i m i l a ra n di ti ss p e c u l a t e dt h a tt h e s ep r o t e i n sh a v e
non-redundant functions [23,24]. In addition, consistent
with deregulation of the mTOR pathway, we also noted
the deregulation of TSC1, a major regulator of mTOR,
in the BHDS-derived tumors (Additional file 2, Figure
S1E).
We also examined transcription levels of genes asso-
ciated with AMPK signaling, as this was a likely can-
didate for signaling based on our observation of
mitochondrial gene set enrichment and the recently dis-
covered indirect interaction between FLCN and AMPK.
AMPK is a key molecule for energy sensing and a regula-
tor of the PGC-1a transcription factor, a potent inducer
of mitochondrial biogenesis (Figure 4A). We noted that
two transcription factors, PGC-1a and TFAM (transcrip-
tion factor A, mitochondrial), were also up-regulated in
the BHDS-derived tumors (Figure 4E and Additional file
2, Figure S1G). Both transcription of mitochondrial genes
and replication of the mitochondrial genome depend on
TFAM function and the TFAM gene is uniquely over-
expressed in the BHDS-derived tumors (for a review of
transcriptional regulators of mitochondria, see [56-58]).
PGC-1a (PPARGC1A) was also highly expressed in the
BHDS-derived tumors as measured by gene expression
profiling. However, the levels of PGC-1a as measured by
qRT-PCR in BHDS tumors were sensitive to the probe/
primer sets used, suggesting that BHDS tumors may have
a difference in the abundance of a particular PGC-1a iso-
form (Additional file 2, Figure S1G). The PGC-1a bind-
ing partner, nuclear receptor peroxisome proliferator-
activated receptor gamma (PPARG) was highly expressed
in BHDS-derived tumors as compared to non-diseased
tissue, sporadic oncocytoma, and chromophobe RCC
(Additional file 2, Figure S1F) while the peroxisome pro-
liferator-activated receptor alpha (PPARA)w a sh i g h e ri n
BHDS-derived tumors versus sporadic oncocytoma and
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Figure 3 A mitochondrial phenotype is the most prominent
molecular feature of BHDS renal tumors. A) Top differentially
expressed gene sets in CC and BHD tumors. The first and second
groups represent those gene sets from MsigDB that are unique to
CC and BHD, respectively, as compared to the other RCC subtypes
given in Figure 1A. The third group is a comparison of the BHD
tumor gene expression data with only CH and ON gene expression
data. B) The most differentially expressed gene set in CC tumor
samples compared to the other RCC subtypes. C) The most
differentially expressed gene set in BHDS tumor samples compared
to the other RCC subtypes. D) Heatmap of enrichment scores for
the thirty most differentially expressed gene sets in BHD versus CH
and ON. On the left is a dendrogram displaying the calculated
pairwise distances between dissimilarities of gene set compositions.
E) The most differentially expressed gene set in BHD tumors as
compared with CH and ON. Note that enrichment values for the
other RCC subtypes are given here for reference in B, C, and E.
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Page 7 of 12chromophobe (data not shown). Moreover, we found a
set of PGC-1a regulated genes, entitled “PGC,” was
highly up-regulated in BHDS-derived samples (Figure
3D). To confirm this “PGC” g e n es e tf r o mM s i g D Bw a s
representative of PGC-1a activation, we generated an
independent gene expression signature from HepG2 cells
that were adenovirally infected with PGC-1a versus con-
trol (Figure 4C, performed by Gaillard et al.) [59].
Although there was only 11.8 percent similarity between
these two independently generated PGC-1a gene sets,
both gene sets were significantly up-regulated in BHDS-
derived patient tumors (Figure 4D). We did not see
expression changes associated with genes encoding the
mitochondria-associated transcription factors NRF-1 and
NRF-2. Taken together, these results indicate that dereg-
ulation of FLCN function by point mutation is associated
with FNIP2 deregulation and perturbation of the PGC-
1a-TFAM signaling axis.
FLCN expression inversely correlates with PGC-1a
activation
Based on the data from the BHDS-derived tumors, we
hypothesized that defects in FLCN may be associated
with increased expression of genes related to mitochon-
dria and OXPHOS. To test this hypothesis, we exam-
ined the relationship between FLCN expression and
gene set enrichment in a variety of other tumor tissue
types, using a data set that includes tumors of the
b r e a s t ,c e r v i x ,c o l o n ,k i d n e y ,l u n g ,l y m p h ,o v a r y ,p a n -
creas, prostate, stomach, thyroid, and vulva, with
matched normal tissue of each tissue type. Using FLCN
expression levels and PGSEA scores of the 1892 gene
sets analyzed previously for this data set, we determined
which gene sets were most related to FLCN gene
expression. Consistent with the loss of FLCN function
in BHDS-derived tumors, the top 20 gene sets identified
were all negatively correlated to FLCN expression and
were primarily related to metabolism and mitochondrial
function (Figure 5A). Specifically, we found that the
PGC gene set and other OXPHOS gene sets were highly
negatively correlated with FLCN expression across these
tumor types (Figure 5B). Though not included in the
initial gene set correlation analysis, our PGC-1a over-
expression signature (Figure 4C) was also negatively cor-
related with FLCN expression (rho, -0.60, p < 0.0001).
Based on our findings, it is likely that a FLCN-PGC-1a-
TFAM signaling axis exists and that lack of FLCN
expression may be an important feature in sporadic
tumors of other organs as it is in BHDS-derived renal
tumors.
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Figure 4 BHDS-derived tumors possess characteristics of an
active PGC-1a-TFAM signaling axis. A) Schematic of FLCN
interacting proteins in signal transduction pathway. B) Relative gene
expression levels for tuberous sclerosis 1 (TSC1) and folliculin
interacting protein 2 (FNIP2) proteins in tumors from patients with
BHDS, ON, CH, and the other RCC subtypes from Figure 1A. C) An
independent PGC-1a signature from over-expression of PGC-1a in
HepG2 cells (GSE5968), showing the top 150 genes (rows) that are
up-regulated in PGC-1a over-expressing cells compared to controls
(columns). Red indicates high expression and blue indicates low
expression. D) Correlation of empirically-derived PGC-1a signature
represented in C compared to the PGC signature from Figures 3A
and 3D, applied to the six RCC subtypes, using Pearson’s correlation.
E) Relative expression of the TFAM transcription factor involved in
mitochondrial biogenesis (all p ≤ 0.01) in gene expression array data
from BHD, CH, ON, and the remaining RCC subtypes, as well as
non-diseased tissue and from qRT-PCR validation of a subset of
those samples.
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To establish the molecular characteristics of tumors that
arise in individuals afflicted with BHDS, we compared
gene expression data from renal tumors of BHDS
patients with expression data from sporadic renal
tumors. Although previous gene expression profiling
studies indicated that renal tumors isolated from indivi-
duals afflicted with von Hippel-Lindau disease are indis-
tinguishable from sporadic clear cell RCC[43], we show
that kidney tumors from patients with BHDS also have
unique genetic and cytogenetic characteristics from
sporadic renal oncocytoma and chromophobe RCC. In
particular, cytogenetic defects that are typical of spora-
dic oncocytoma and chromophobe RCC, including
defects of chromosome 19, loss of chromosome 1, and
translocations involving chromosome 11, were largely
absent from BHDS-derived tumors. Interestingly, we did
not find differences in FLCN expression by either our
gene expression arrays nor by qRT-PCR, suggesting that
the FLCN mRNA transcript may not be subject to
nonsense-mediated mRNA decay. However, several indi-
vidual genes are differentially expressed between BHDS-
derived tumors and the sporadic tumors. One gene in
particular, DAPL1 (death-associated protein-like 1), is
expressed at a high level in BHDS-derived tumors.
Although the function of DAPL1 is not known, it was
originally termed early epithelial differentiation asso-
ciated (EEDA) for its expression in stratified squamous
epithelium, specifically in a population of cells of the
hair follicle [60]. High expression of this gene in BHDS-
derived tumors is a potentially interesting finding given
the clinical presentation of fibrofolliculomas that arise in
BHDS-afflicted individuals.
Several recent reports have implicated FLCN in the
energy and nutrient signaling pathway through its inter-
actions with FNIP1 and FNIP2 and its indirect interac-
tion with AMPK (Figure 4A). These studies have also
suggested that FLCN impacts the mammalian target of
rapamycin (mTOR) related components of the PI3K-Akt
signal transduction pathway [22]. Consistent with the
existence of a FLCN-mTOR relationship, treatment with
the specific mTOR inhibitor, rapamycin, delays the
death of mice that possess targeted deletion of FLCN in
the kidney [61,62]. We noted high expression of FNIP2
and TSC1 in BHDS-derived tumors, implicating a novel
link between FLCN and both AMPK- and mTOR-
mediated signaling and transcription. However, we did
not see evidence of PI3K-Akt activation in BHDS-
derived tumors using an expression signature that was a
robust predictor of PI3K-Akt pathway activation in
other renal tumors [53], nor did we see consistent
enrichment of the three mTOR activation signatures
from the MsigDB in the BHDS patient samples. It is
possible that the up-regulation of TSC1 we have
observed represents a feedback effect from the somatic
mutation in FLCN. One potential rational for this obser-
vation is that is has recently been noted that activation
of mTOR controls mitochondrial gene expression
through signaling with PGC-1a [63]. Moreover, mTOR-
mediated control of mitochondrial gene expression is
inhibited by application of rapamycin. Our results sug-
gest that the effects of rapamycin noted in FLCN loss-
of-function mice may be through the mitochondrial
effects of mTOR activation as opposed to activation of
PI3K-Akt.
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Figure 5 FLCN expression negatively correlates with PGC-1a
activation. A) The twenty most highly correlated gene sets with
FLCN expression levels, followed by their respective Spearman rho
correlation coefficients. Bold font indicates gene sets also shown in
Figure 3. The dendrogram is based on gene set dissimilarity scores
(see Materials and Methods). B) Plot of FLCN expression and the
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Data for A) and B) are from the Expression Project for Oncology -
International Genomics Consortium.
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Page 9 of 12Throughout our analysis, we observed that one spora-
dic renal oncocytoma co-clustered with the BHDS-
derived tumors and showed strong PGC-1a-related gene
expression (Figure 1B, F). This tumor sample also lacked
the cytogenetic features typical of sporadic oncocytomas,
such as loss of chromosome 1, deregulation of CCND1,
and over-expression of chromosome 19 genes (Figure
2). Interestingly, this individual presented with renal
oncocytoma at the age of 34 years old, while the median
age of sporadic renal oncocytoma is between 65-70
[7,64]. Given that early age at diagnosis (under age 50)
is often a feature of hereditary disease, we sequenced
the entire FLCN open reading frame from non-diseased
kidney tissue of this patient and only identified a com-
mon single nucleotide polymorphism within the 5’ UTR
[11]. Though somatic mutations in FLCN occur in
approximately 10 percent of sporadic tumors, we lacked
the tissue required to determine the FLCN status in the
tumor itself. However, these results suggest that a sepa-
rate BHDS-like group of sporadic renal oncocytomas
could exist in the population, genetically distinct from
other sporadic renal tumors.
Finally, although these DCT-derived tumors are
genetically distinct, BHDS-derived tumors, sporadic
renal oncocytoma, and chromophobe RCC share their
histological and mitochondrial/OXHPOS gene expres-
sion characteristics. Development of oncocytomas in
organ sites outside of the kidney are also associated
with prominent mitochondrial DNA mutations, a high
production of mitochondria, and deregulated OXPHOS
gene expression [65,66]. In renal oncocytoma and other
mitochondrial myopathies, up-regulation of mitochon-
drial gene expression is thought to represent a feedback
mechanism to compensate for mitochondrial damage
[67,68]. In this study, we show that the mitochondrial
expression phenotype is even more pronounced in sam-
ples that harbor FLCN mutations. The enhanced mito-
chondrial gene expression in BHDS samples suggests
that wild-type FLCN is important for efficient mitochon-
drial function and that lack of functional FLCN leads to
a yet unknown mitochondrial dysfunction. Deregulation
of mitochondrial proteins has recently been identified in
sporadic oncocytoma and chromophobe RCC [30].
Future studies will therefore help to clarify the role of
FLCN in mitochondrial function.
Conclusions
Our results support a genetic distinction between
BHDS-associated tumors and other sporadic renal neo-
plasias. In addition, we found that deregulation of the
PGC-1a-TFAM signaling axis is most pronounced in
renal tumors that harbor FLCN mutations and in
tumors from other organs that have relatively low
expression of FLCN. These results are consistent with
the recently discovered interaction between FLCN and
AMPK and support a model in which FLCN is a regula-
tor of mitochondrial function.
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